Cancers du sein / Du diagnostic au suivi

Objectives

The guide operationalises France’s Cancer Plan 2014–2019 for breast cancer by supporting outpatient care pathways led in part by general practitioners. The wider plan prioritises curing more people, preserving continuity and quality of life, strengthening prevention and research, and improving governance and organisation.[1]Its immediate purpose is to provide general practitioners with a concise account of women’s breast-cancer care pathway, from diagnosis to follow-up.[1]

The pathway covers diagnostic assessment, initial work-up, treatment strategy, management of principal treatment adverse effects, longer-term follow-up, wider medical care, and practical resources for patients and clinicians.[2]It addresses a common condition: projected 2015 figures for France were 54,062 new breast-cancer cases and 11,913 deaths, while estimated five-year net survival was about 87%.[3]

The clinical objectives span early identification, individualised treatment, recurrence surveillance, management of sequelae, supportive care, and prevention of avoidable health risks. Improved outcomes are linked to therapeutic advances and increased detection of early-stage cancers through screening.[3]

• Support diagnosis through clinical history, examination, imaging and tissue confirmation, while recognising presentations through screening or clinical signs.[4][5]
• Identify hereditary-cancer concerns, as an estimated 5–10% of breast cancers are associated with genetic predisposition, commonly involving BRCA1 or BRCA2 mutations.[4]
• Guide treatment according to prognostic features, predictive factors including hormone-receptor and HER2 status, breast volume, and patient preferences.[6][7]
• Provide systemic treatment where indicated, including chemotherapy, targeted therapies and hormone therapy when at least one hormone receptor is expressed; hormone therapy is described as lasting at least five years.[8]
• Stabilise metastatic disease where possible, improve quality of life and achieve remissions of variable duration.[8]
• Detect recurrence, contralateral or new breast cancer, second cancers, late complications and sequelae, while supporting treatment adherence, return to work, medico-social needs and healthy behaviours.[9]
• Reduce modifiable risks through smoking and alcohol cessation, physical activity, prevention of weight gain and obesity, and attention to cardiovascular health.[10]

Implementation

The delivery model places the general practitioner at the centre of a shared pathway with specialist treatment teams, from initial presentation through long-term follow-up.[3][2]Care decisions are informed by multidisciplinary consultation, discussed formally with the patient, and recorded in an individualised care programme shared with the patient and designated doctors.[7]

Specialist referral is supported by a complete clinical file, including biopsy results and hormone-receptor and HER2 findings.[6]Treatment and follow-up should also address pain, nutritional vulnerability, psychological distress and social fragility, with supportive care for patients and relatives.[7]The guide was developed from good-practice recommendations using a methodology described by the National Cancer Institute, France’s agency for health and scientific expertise and cancer-control coordination.[1]

Implementation is supported by professional and patient resources, including documents, websites, telephone platforms and an online interactive version hosted on e-cancer.fr.[1][2]The Cancer Info telephone service is a partnership between the National Cancer Institute and the French League Against Cancer, offering practical, medical, social, psychological and legal information and support.[11]

• Undertake clinical assessment covering tumour characteristics, relevant personal and family history, lymph-node areas and signs that may suggest metastatic disease.[5]
• Use bilateral mammography systematically, supplementing it with ultrasound when mammography is non-informative, doubtful or undertaken in dense breasts; use biopsy to confirm suspicious lesions and establish receptor and HER2 status.[5]
• Coordinate surgery, radiotherapy, systemic therapies and supportive interventions through specialist and primary-care collaboration, including early adverse-effect management.[7][8]
• Exchange information in both directions between the general practitioner and specialist team during shared follow-up.[9][12]
• Review patients clinically every three to six months for five years and annually thereafter, with annual breast imaging while treatment would remain feasible if a lesion were found; adapt the schedule to prognosis, initial severity and patient characteristics.[9]
• Monitor treatment sequelae, including lymphoedema, cardiovascular, neurological, cognitive, musculoskeletal, sexual, gynaecological and bone-health effects, and refer to relevant specialists when required.[12][13]
• Support smoking cessation from the beginning of care, as the general practitioner has a major role; nicotine-replacement treatment for patients with cancer was reimbursed up to 150 euros annually from June 2015, subject to a dedicated prescription.[14]
• Incorporate reproductive counselling, vaccination advice and organised screening for other cancers into general-practice follow-up.[10]

A multidisciplinary group comprising general practitioners, nurses, physiotherapists, oncologists, surgeons, radiologists, radiotherapists, pharmacists and National Cancer Institute staff contributed to the material.[11][15]The excerpts do not specify a programme budget, formal implementation timetable, performance framework, audit process or broader accountability arrangements.[16][15]

Monitoring & Evaluation

Monitoring is primarily clinical and surveillance-based, centred on detecting recurrence, second cancers, and treatment-related complications through shared follow-up between general practitioners and specialist teams. The excerpts do not set out a programme-level evaluation framework, performance indicators, audit cycle, routine reporting system, or formal accountability structure for the guide or Cancer Plan implementation.[3][6][7][8][12][16]

• Use projected 2015 burden and outcome figures as contextual evidence: France was estimated to have 54,062 new breast-cancer cases and 11,913 deaths, while estimated five-year net survival was approximately 87%.[3]
• Document diagnosis through imaging, tissue confirmation, and pathological characterisation, including hormone-receptor and human epidermal growth factor receptor 2 status, to inform prognosis and treatment selection.[5][6]
• Record multidisciplinary treatment decisions in an individualised care programme shared with the patient and designated doctors.[7]
• Conduct shared clinical follow-up every three to six months for five years and annually thereafter for life, using history-taking and examination to identify local or distant recurrence, contralateral breast cancer, second cancers, late complications, and sequelae.[9]
• Undertake mammographic surveillance, with or without ultrasound, one year after the initial mammogram and at least six months after radiotherapy, then annually while treatment would remain possible if a lesion were identified.[9]
• Adapt surveillance frequency to the severity and prognosis of the initial cancer and to genetic and other individual characteristics.[9]
• Avoid routine biological monitoring, serum tumour-marker testing, and systematic additional imaging outside clinical trials or selected circumstances; undertake further investigations when symptoms or clinical signs indicate a need.[9]
• Monitor early treatment effects, including wound complications, lymphoedema, radiation skin reactions, fatigue, digestive and haematological toxicity, stomatitis, alopecia, and cardiovascular toxicity.[8][17]
• Assess late effects and sequelae, including cardiovascular, neurological, cognitive, sexual, musculoskeletal, gynaecological, and bone-health problems.[12][13]
• Monitor left ventricular ejection fraction regularly for cardiotoxicity associated with anthracyclines and targeted therapies.[13]
• Use clinical assessment and the DN4 questionnaire for peripheral neuropathy, assess cognitive function where cognitive toxicity is suspected, and investigate potential causes of fatigue, including anaemia, malnutrition, and depression.[13]
• Investigate abnormal uterine bleeding promptly with pelvic ultrasound because of endometrial-cancer risk, and monitor bone density at the start of aromatase-inhibitor therapy and at regular intervals thereafter.[13][10]
• Maintain at least annual clinical surveillance for women treated with tamoxifen because of endometrial-cancer risk.[10]
• Assess recurrence before attributing late-onset lymphoedema to treatment effects, and recognise the breast, ovary, and endometrium as principal sites of second-cancer risk after breast cancer.[12][10]
• Require health professionals to report every suspected adverse effect.[18]
• Maintain regular surveillance for lobular carcinoma in situ, which is described as a precancerous lesion with a long-term risk of invasive cancer.[18]
• Apply governance safeguards through expert declarations of interest; the National Cancer Institute reported no identified risk of conflicts of interest following its analysis.[15]

Costing & Financing

Costing and financing information is very limited. No overall budget, treatment-cost estimate, financing framework, resource-mobilisation plan, funding-gap analysis, allocation mechanism, or economic assumption is specified for the guide, breast-cancer pathway, or wider Cancer Plan in the supplied material.[1][6][8][9][16]

• Provide reimbursement for nicotine-replacement treatments for patients with cancer, including patches and chewing gum, up to 150 euros per year from June 2015, subject to a prescription exclusively for these products.[14]
• Recognise that a hydrating nail varnish identified as a preventive measure for nail toxicity is not reimbursed.[14]
• Use existing informational resources, including the Cancer Info telephone service, which is supported by the National Cancer Institute and the French League Against Cancer and provides practical, medical, social, psychological, and legal information and support.[11]
• Note that the excerpts do not specify the financial implications, staffing requirements, or funding sources for multidisciplinary care, imaging surveillance, supportive care, adverse-effect reporting, or online and telephone information resources.[7][9][18][2]